Five Takeaways from the Second Circuit’s Namenda Decision
Bloomberg BNA Antitrust & Trade Regulation Report (July 24, 2015)

Top 5 Developments In Reverse Payments Over The Last Year
Law360 (January 23, 2015)

Can I Patent This? Tales Of Patent Eligibility From Examination Of U.S. Patent Applications In Class 435
Bloomberg BNA: Life Sciences Law & Industry Report (September 19, 2014)

On the first Monday in October, will IP still be in the Supreme Court’s spotlight?
InsideCounsel (September 12, 2014)

Trade Secrets: You May Have More Than You Think
Inside Counsel (August 29, 2014)

Trade Secret Protection is the new Black Maybe
Inside Counsel (August 19, 2014)

Its Hard Out Here for a Patent
Inside Counsel (August 1, 2014)

Patent Claim Construction Takes Center Stage
Inside Counsel (7/18/2014)

After Actavis: Crafting Pharmaceutical Settlements that Avoid Antitrust Scrutiny
(July 10, 2014)

One of These Days... Bang! Zoom! Why Technology Innovators Should Pay Attention to Alice
Inside Counsel (July 3, 2014)

5 Red Flags In Pharmaceutical Settlements
Law360 (May 13, 2014)

Clones Not Patent-Eligible? 
(May 9, 2014)

Personalized Medicine and Patent Eligibility under 35 U.S.C. § 101
(April 25, 2014)

Finding the Line Separating Infringement and Exempt Uses:Enforcing Biotechnology Patents in View of 35 U.S.C. § 271(e)(1)
Bloomberg BNA: Life Sciences Law & Industry Report (April 4,2014)

The Continuing Saga of Mayo v. Prometheus
Law360 (February 25, 2014)

Timing Is Everything
Intellectual Property Magazine (September 9, 2013)

The Supreme Court Identifies Categories of Patent-Eligible and Patent-Ineligible DNA Sequences
Bloomberg BNA: Life Sciences Law & Industry Report (August 9, 2013)

The Federal Circuit Reaffirms the Patent Eligibility of Certain Inventive Products and Methods Based on Human DNA Sequences: What Will the Supreme Court Say About That?
Bloomberg BNA: Life Sciences Law & Industry Report (October 5, 2012)

Unanimous Supreme Court Refines the Scope of Patent-ineligible Processes, Potentially Exposing Vulnerability of Patents in Life Science Technologies
Bloomberg: Life Sciences Law & Industry Report (April 6, 2012)

The America Invents Act: Changes in the Patent Laws of Special Interest to the Life Sciences Industry
Bloomberg: Life Sciences Law & Industry Report (November 4, 2011)

Co-author, Reviewing Joint Infringement
IP Law360 (May 9, 2011)

Co-author, Federal Circuit Reaffirms a Strong Separate Written Description Requirement for Patent Claims
Bloomberg Law Reports - Intellectual Property (June 5, 2010)


New York Attorneys Recognized as 2016 “Super Lawyers” and “Rising Stars”

New York Attorneys Recognized as 2015 “Super Lawyers” and “Rising Stars”

Matthew McFarlane Files Amicus Brief on Behalf of New York Intellectual Property Law Association

Gene, Method Patent Rulings Said Top Issues for Life Sciences This Year

Bloomberg BNA Study Analyzes the Impact of Recent Supreme Court Decisions That Leave Life Sciences Industry Under Cloud Of Uncertainty: Report Released at 2014 BIO International Convention Explores Important Changes to Patent Process

USPTO's Power To Nix Verdicts Ripe For Supreme Court


Protecting Valuable IP in the Face of New Challenges to Patent Eligibility
BIO World Congress on Industrial Biotechnology, Montreal, Canada (July 21, 2015)

Patent Eligibility from the Trenches: Practical Implications of the Supreme Court’s Prometheus and Myriad Decisions
BIO International Convention, San Diego, California (June 23-26, 2014)

Mid-Year Case Law in Review: Trade Secrets
AIPLA Spring Meeting, Philadelphia, Pennsylvania (May 15-17, 2014)

Gene Patent Forum
LifeScience Alley, Minneapolis, Minnesota (October 15, 2013)

Supreme Court and Federal Circuit Cases Regarding Laws of Nature
New York Intellectual Property Law Association, New York, New York (January 17, 2013)


Enforcement Challenges for BioTech Patents

Is BioTech Patentable Subject Matter?


Recent Legal & Economic Developments That Affect Your Biotech Business
Learn how inventorship and ownership of patent rights have given rise to disputes between biotech companies.
(March 29, 2016, 1:00 P.M. CST)